PRL and schizophrenia: In conclusion, the results of this post hoc analysis of adolescents and young adults with schizophrenia revealed that long-term treatment with lurasidone, at doses of 40–160 mg/day, was safe, well tolerated, and effective in maintaining improvement in schizophrenia symptoms and preventing relapse while having minimal effects on weight, metabolic parameters, and prolactin.